Spain as an example worldwide. The immunization campaign against respiratory syncytial virus (RSV) fills the pediatric ICUs with children with bronchiolitis every winter. But this year things could be different. More than 800,000 children under six months of age in our country now have access to nirsevimab, developed by Sanofi and AstraZeneca.
It is a monoclonal antibody that will act as a shield against the pathogen, freeing children from the condition of trying to fill their lungs with oxygen, freeing parents from hours of anguish and absences from work, and freeing the health system from the pressure of care in hospitals and consultations. .
Our country, along with France and the US, is one of the models where the French company is going to validate the real-life effectiveness of the results obtained in the trials. In these, it has been shown that income is reduced by up to 80%.
Raquel Tapia, the general director of the French laboratory in our country, proudly says that “we have managed to work with all levels: Ministry, departments of the autonomous communities, scientific societies… and we have launched the campaign throughout the country ».
What seems easy, is not. For anyone who does not know our health system, they should realize that making a drug available to patients requires negotiation not only with Health, but with the 17 ‘ministries’ that can make up the regional ministries. “We feel very proud,” insists Tapia. Because public-private collaboration in Health, as Pedro Sánchez alluded to in his investiture speech, is a formula that works. “We are going to promote greater public-private collaboration in R&D&I,” said Sánchez.